Development of Chimeric Antigen Receptor‐Modified NK Cells for the Immunotherapy of Adult T‐Cell Leukemia/Lymphoma
European Journal of Haematology · 2026-08 · 117 (2) · 481-491
DOI: 10.1111/ejh.70199 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 03.05.2026. Verfasst von Yuichiro Uchida und 7 weiteren Autor:innen. Beteiligte Einrichtung: SUDx-Biotec Corporation, Kagoshima, Japan. Hauptthemen laut MEDLINE: Leukemia-Lymphoma, Adult T-Cell, Receptors, Chimeric Antigen, Killer Cells, Natural, Immunotherapy, Adoptive. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Adult T‐cell leukemia/lymphoma (ATL) is an aggressive hematological malignancy with a poor prognosis and limited therapeutic options. ATL cells exhibit aberrant surface glycosylation patterns resulting from dysregulated glycosyltransferase expression, representing a potentially tumor‐specific therapeutic target. We previously isolated an ATL‐specific single‐chain variable fragment (scFv), S1TSCFR3‐1, that selectively binds to ATL cell surface glycans. In this study, we engineered natural killer (NK) cells to express a chimeric antigen receptor (CAR) incorporating S1TSCFR3‐1 and evaluated their therapeutic potential against ATL. In vitro, CAR‐NK cells exhibited dose‐dependent cytotoxicity against ATL cell lines, mediated primarily through enhanced granzyme B production, whereas no augmentation of cytotoxic activity was observed against non‐ATL cell lines. S1TSCFR3‐1 binding was detected in PBMCs from 3 of 7 ATL patients, and CAR‐NK cells demonstrated significant cytotoxicity against PBMCs from a binding‐positive patient. In a xenograft mouse model, administration of irradiated CAR‐NK cells partially suppressed tumor burden as evidenced by reduced serum hsIL‐2R levels, although survival benefit did not reach statistical significance. These findings suggest that CAR‐NK cell therapy targeting ATL‐associated aberrant glycan epitopes represents a potentially valuable therapeutic approach warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- SUDx-Biotec Corporation, Kagoshima, Japan.
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
- Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
ORCID-Profile: Yuichiro Uchida
Zitieren
APA
Uchida, Y., Tateo, S., Wakao, M., Shinchi, H., Sawayama, H., Fukumoto, A., Yoshimitsu, M., & Suda, Y. (2026). Development of Chimeric Antigen Receptor‐Modified NK Cells for the Immunotherapy of Adult T‐Cell Leukemia/Lymphoma. European Journal of Haematology, 117(2), 481-491. https://doi.org/10.1111/ejh.70199
Vancouver
Uchida Y, Tateo S, Wakao M, Shinchi H, Sawayama H, Fukumoto A, et al. Development of Chimeric Antigen Receptor‐Modified NK Cells for the Immunotherapy of Adult T‐Cell Leukemia/Lymphoma. European Journal of Haematology. 2026;117(2):481-491. doi:10.1111/ejh.70199
BibTeX
@article{Uchida2026,
author = {Uchida, Yuichiro and Tateo, Seigo and Wakao, Masahiro and Shinchi, Hiroyuki and Sawayama, Hayate and Fukumoto, Akira and Yoshimitsu, Makoto and Suda, Yasuo},
title = {Development of Chimeric Antigen Receptor‐Modified NK Cells for the Immunotherapy of Adult T‐Cell Leukemia/Lymphoma},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {2},
pages = {481--491},
doi = {10.1111/ejh.70199}
}
EUVIMED